Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot47410.32687/0869-866X-2021-29-1-59-65Научная статьяThe comparative characteristic of approaches to monitoring and evaluation of morbidity of psoriasis in the Russian Federation and the countries of the European regionBagaevaA. M.dr.khadzhaeva@gmail.comNashkhoevM. R.-MadyanovaV. V.-ToskinI. A.-The Federal State Autonomous Educational Institution of Higher Education «The I. M. Sechenov First Moscow State Medical University» (Sechenov University) of Minzdrav of RussiaThe Republican Dermatovenerology Dispensary15122021291596506042021Copyright © 2021,2021The psoriasis is chronic inflammatory dermatitis that is accompanied by severe damage of skin and musculoskeletal system and affects functions of other organs and systems. The epidemiological data concerning prevalence and morbidity of psoriasis all over the world varies significantly. The article presents comparative characteristic of approaches to monitoring and evaluation of psoriasis morbidity in the Russian Federation and in the countries of the European region. The differences were revealed such as absence both of indices to evaluate quality of life of patients with psoriasis and specific population epidemiological studies in national system of monitoring and evaluation of the Russian Federation.psoriasisprevalencemorbidityquality of lifemonitoringevaluationпсориазраспространенностьзаболеваемостькачество жизнитрудоспособностьсоциально-экономические показателимониторингоценкаworking abilityж social economic indicator1.International Federation of Psoriasis Associations (IFPA) World Psoriasis Day website. Режим доступа: https://ifpa-pso.com/our-actions/world-psoriasis-day2.Скрипкин Ю. К. Кожные и венерические болезни. М.: Триада-фарм; 2001. С. 361-73.3.Знаменская Л. Ф. Заболеваемость и распространенность псориаза в Российской Федерации. Вестник дерматологии и венерологии. 2012;(5):20-9.4.Palota T., Szepietowski J. C., Pec J. A survey of disease severity, quality of life, and treatment patterns of biologically naive patients with psoriasis in central and eastern Europe. Acta Dermatovenerol. Croat. 2010;18:151-61.5.Мордовцев В. Н., Сергеев А. С., Алиева П. М., Кошечкин В. А. Ассоциация псориаза с гиперлипопротеинемией, мозговым инсультом, ишемической болезнью сердца, инфарктом миокарда и сахарным диабетом. Вестник дерматологии. 1982;(9):4-8.6.Янышева А. В. Метаболические нарушения при псориатическом артрите. Сибирский медицинский журнал. 2009;(2):25-8.7.DCCT Research Group Reliability and validity of a diabetes quality of life measure for the diabetes control and complications trial (DCCT). Diabetes Care. 1998;11:725-32.8.Michelson H., Bolund C., Brandberg Y. Multiple chronic health problems are negatively associated with health related quality of life (HRQOL) irrespective of age. Qual. Life Res. 2000;9:1093-104.9.Starfield B., Lemke K. W., Bernhardt T. Comorbidity: Implications for the Importance of Primary Care in Case Management. Ann. Fam. Med. 2003;1(1):8-14.10.Sommer D. M., Jenisch S., Suchan M., Christophers E. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006;298(7):321-8.11.Van Weel C., Schellevis F. G. Comorbidity and guidelines: conflicting interests. Lancet. 2006;367:550-1.12.Shapiro J., Cohen A. D., David M., Hodak E. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case control study. J. Am. Acad. Dermatol. 2007;56 (4):629-34.13.Gottlieb A. B., Chao C., Dann F. Psoriasis comorbidities. J. Dermatol. Treat. 2008;19(1):5-21.14.Guenther L., Gulliver W. Psoriasis comorbidities. J. Cutan Med. Surg. 2009;13(2):77-87.15.Aurangabadkar S. J. Comorbidities in psoriasis. Indian J. Dermatol. Venereol. Leprol. 2013;79(7):10-7.16.Yeung H., Takeshita J., Mehta N. N. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173-9.17.Cardiovascular psoriasis comorbidities, treatment with atorvastatin. J. Am. Acad. Dermatol. 2014;70(1):165-75.18.Мишина О. С. Заболеваемость псориатическим артритом в России: тенденции на современном этапе и перспективы. Научно-практическая ревматология. 2015;53(3):18-2119.Ермошина Е. А., Сонин Д. Б. Анализ заболеваемости дерматозами с временной утратой трудоспособности в амбулаторно-поликлинических условиях. 3-й Всероссийский конгресс дерматовенерологов. М.; 2009.20.WHO. World psoriasis day - document EB133.R2, agenda item 6.2. May 30,2013. Режим доступа: http://apps.who.int/gb/ebwha/pdf_files/EB133/B133_R2-en.pdf; Global report on psoriasis. 2016. Режим доступа: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (дата обращения 02.04.2018).21.Данные Федеральной службы государственной статистики РФ. Режим доступа: www.gks.ru22.Vena G. A., Altomare G., Ayala F., Berardesca E., Calzavara-Pinton P., Chimenti S. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J. Dermatol. 2010;20(5):593-8.23.Parisi R. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Investigat. Dermatol. 2013;133(2):377-85.24.Каверина Е. В., Фомина А. В., Репина Е. Ю. Оценка оказания медицинской помощи пациентам с хроническими заболеваниями кожи и подкожной клетчатки: Методические рекомендации. М.: РУДН; 2016. 22 с.25.Augustin M., Glaeske G., Radtke M., Christophers E., Reich K., Schaefer I. Epidemiology and comorbidity of psoriasis in children. Br. J. Dermatol. 2010;162:633-6.26.Jacobson C. C., Kumar S., Kimball A. B. Latitude and psoriasis prevalence. J. Am. Acad. Dermatol. 2011;65(4):870-3.27.Danielsen K., Olsen A. O., Wilsgaard T., Furberg A. S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br. J. Dermatol. 2013;168:1303-10.28.Bø K., Thoresen M., Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatol. Basel Switz. 2008;216(1):40-5.29.Shao C. G., Zhang G. W., Wang G. C. Distribution of psoriasis in China: a nationwide screening. Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll. 1987;2(2):59-65.30.Chen G.-Y., Cheng Y.-W., Wang C.-Y., Hsu T.-J., Hsu M. M.-L., Yang P.-T. Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. J. Formos Med. Assoc. 2008;107(1):21-9.31.Yang Y.-C., Cheng Y.-W., Lai C.-S., Chen W. Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. J. Eur. Acad. Dermatol. Venereol. 2007;21(5):643-9.32.Li M.-J., Wang P., Wu W.-W., Fu L., Cai M., Chen M.-X. An epidemiological survey of psoriasis in 18 cities in Hainan province of China. J. Dermatol. 2012;39(Suppl. 1):243-4.33.Chang Y.-T., Chen T.-J., Liu P.-C., Chen Y.-C., Chen Y.-J., Huang Y.-L. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm. Venereol. 2009;89(3):262-6.34.Yip S. Y. The prevalence of psoriasis in the Mongoloid race. J. Am. Acad. Dermatol. 1984;10(6):965-8.35.Ding X., Wang T., Shen Y., Wang X., Zhou C., Tian S. Prevalence of psoriasis in China: a population-based study in six cities. Eur. J. Dermatol. 2012;22(5):663-7.36.Wang R., Cao L., Zhou C., Zhang J. Prevalence of 15 skin diseases in adolescents from Liangshan prefecture in Sichuan Province. Chin. J. Dermatol. 2012;45(4):270-2.37.Kubota K., Kamijima Y., Sato T., Ooba N., Koide D., Iizuka H. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450.38.Stern R. S., Nijsten T., Feldman S. R., Margolis D. J., Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. 2004;9(2):136-9.39.Boehncke W.-H., Schon M. P. Psoriasis. Lancet. 2015;386(9997): 983-94.40.Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010: Results by Cause 1990-2010. Seattle: IHME; 2012.41.Prins M., Krabbe P. F. M., Swinkels Q. O. J., de Boo T., van de Kerkhof P. C. M., van der Valk P. G. M. The effect of treatment on quality of life in psoriasis patients. Acta Derm. Venereol. 2005;85(4):304-10.42.Renzi C., Picardi A., Abeni D., Agostini E., Baliva G., Pasquini P. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch. Dermatol. 2002;138(3):337-42.